Plasma Copeptin and Risk of Lower-Extremity Amputation in Type 1 and Type 2 Diabetes.

Louis Potier Ronan Roussel Michel Marre Petter BjornstadDavid Z CherneyRay El BoustanyFrédéric FumeronNicolas VenteclefJean-François Gautier Samy Hadjadj Kamel MohammediGilberto Velho

Published in: Diabetes care (2019)

Baseline plasma copeptin is associated with cumulative incidence of LEA in cohorts of people with both type 1 and type 2 diabetes and may help to identify patients at risk for LEA.

Keyphrases

type diabetes
end stage renal disease
ejection fraction
newly diagnosed
chronic kidney disease
glycemic control
cardiovascular disease
insulin resistance
risk factors
prognostic factors
metabolic syndrome
weight loss